Market News

Minimally invasive medical care rose more than 16%. As of press time, it rose 16.38% to HK $17.9, with a turnover of HK $67.9862 million. Minimally invasive robots rose more than 7%, with a turnover of nearly HK $10 million.

On the face of the news, National Healthcare Security Administration issued "National Healthcare Security Administration's reply to recommendation No. 8427 of the Fifth session of the 13th National people's Congress" on September 1st, pointing out that in the process of centralized volume procurement, medical institutions are based on historical usage, combined with clinical use and medical technology progress to determine the procurement volume. As the clinical use of innovative medical devices is not yet mature and the amount of use is temporarily difficult to predict, it is still difficult to implement the quantity mode. In the process of centralized volume procurement, the proportion of volume is reasonably determined according to the characteristics of clinical use, the pattern of market competition and the number of selected enterprises, and a certain market is set aside to provide space for innovative products to open up the market.

Citic Construction Investment said in a statement that, based on the relevant policy views of the recent Medical Insurance Bureau, the agency believes that the policy of medical insurance for innovative devices is marginal: 1) the clinical use of innovative medical devices is not yet mature, and the use of innovative medical devices is difficult to estimate for the time being. it is difficult to implement the quantity method; 2) in the process of centralized volume procurement, set aside a certain market to provide space for innovative products to open up the market. 3) improve the networking mechanism of the centralized pharmaceutical procurement platform to help new medical devices participate in market transactions smoothly; 4) study and improve relevant policies to guide all localities to timely bring qualified innovative medical consumables into the scope of medical insurance payment according to procedures; 5) in the process of promoting the reform of DRG/DIP medical insurance payment methods, support innovative medical consumables in accordance with relevant regulations and procedures. Up to now, the State Drug Administration has approved the registration and listing of 173 innovative medical devices, mainly related to cardiovascular intervention, IVD, medical imaging, peripheral intervention, surgical robots, auxiliary diagnosis software, tumor treatment and other fields. This catalogue may be of reference significance for National Healthcare Security Administration to formulate health insurance payment policies related to innovative medical devices.